Today: 14 June 2026
Vedanta hits fresh 52-week high near Rs 630 on demerger trade; broker targets stretch to Rs 686
7 January 2026
1 min read

Vedanta hits fresh 52-week high near Rs 630 on demerger trade; broker targets stretch to Rs 686

MUMBAI, January 7, 2026, 23:15 (IST)

  • Vedanta touched a 52-week high of 629.90 rupees and closed near flat at 622 rupees
  • Broker targets run from 625 to 686 rupees as the group pushes a five-way demerger plan
  • The stock’s RSI climbed to 78.6, a level traders often tag as “overbought”

Vedanta Ltd shares touched a 52-week high of 629.90 rupees on Wednesday before giving back most of the move, ending almost flat at 622 rupees.

The jump mattered because it came in a choppy session for Indian stocks, with investors scanning trade and geopolitical headlines ahead of the earnings season. “Markets remain sensitive to trade and geopolitical developments,” said Hitesh Tailor, a research analyst at Choice Equity Broking. Reuters

Brokerage targets have moved up as the rally has stretched into a month-long run. Kotak Securities has a target of 650 rupees, Investec has raised its target to 635 rupees, and Nuvama put fair value at 686 rupees, according to local media reports.

Much of that optimism hangs on Vedanta’s planned demerger — a carve-up into stand-alone listed businesses — which investors see as a way to put cleaner valuations on each unit. It also sets up a string of milestones in early 2026, including quarterly results and regulatory steps tied to the split.

Under the plan, the group would separate aluminium, oil and gas, iron and steel, and power into distinct listed entities, while the parent would keep its stake in Hindustan Zinc and “future-facing” businesses. Shareholders are set to receive equity shares in each of the four new entities in proportion to their existing holdings.

Emkay Global, which had a 625-rupee target on Vedanta, argued Hindustan Zinc’s exposure to silver was still not fully reflected in valuations. The brokerage estimated EBITDA — a measure of operating profit — at 258 billion rupees at spot prices versus 220 billion rupees in consensus forecasts, and said “silver exposure is underpriced”; Trendlyne data showed 13 analysts with a “buy” view on Vedanta. Goodreturns

Nuvama expects EBITDA to rise at a 16% compound annual growth rate (CAGR), or average yearly pace, over FY25-FY28, helped by lower aluminium cost of production and higher volumes. It also forecast consolidated net debt falling to 61,000 crore rupees by end-FY27, part of a broader deleveraging pitch that has stayed in focus for the group.

But the run has started to look stretched on the charts: Vedanta’s 14-day relative strength index (RSI), a momentum indicator, rose to 78.6, above the 70 level many traders treat as overbought. The demerger still needs other regulatory approvals, and Vedanta said a customs penalty and fine on its Balco unit would not have a material financial impact.

Stock Market Today

  • Top British Growth Stocks to Watch in June 2026: Raspberry Pi and Gamma Communications
    June 14, 2026, 3:22 AM EDT. British growth stocks are gaining momentum in 2026 with Raspberry Pi (LSE:RPI) surging nearly 240% year-to-date. Analysts remain bullish, raising 2026 revenue forecasts by 42% amid strong demand from AI and industrial sectors despite margin pressures from rising LPDDR4 DRAM costs. Meanwhile, Gamma Communications (LSE:GAMA), a cloud communications provider, reported 11% revenue growth in 2025 but faces short-term earnings pressure due to acquisition costs. Institutional analysts view current share price weakness as a potential buying opportunity, with a median 12-month price target 51% above current levels. Both stocks offer compelling long-term growth but carry risks from supply chain costs and increased debt from recent acquisitions.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Previous Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none
Next Story

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none

Go toTop